Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab With or Without Cabozantinib in Resected Mucosal Melanoma
NCT05111574Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2022
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of cabozantinib in mucosal melanoma (MM) (3 arms), sponsored by National Cancer Institute. Primary endpoint: Recurrence-Free Survival at 5 years. Started Aug 2022; status: active, not recruiting.
02
Drugs
cabozantinib
03
Conditions
mucosal melanoma (MM)
Beyond the preview
Go deeper on NCT05111574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05111574.